CD274 and small cell lung carcinoma: The CASPIAN study, which explored the use of the PD‐L1 inhibitor durvalumab combined with chemotherapy as first‐line treatment for ES‐SCLC, revealed that the durvalumab plus EC/EP group exhibited a significantly longer median OS than the chemotherapy group (13.0 months vs 10.3 months, p = 0.0047), with a 27% risk reduction of death (HR = 0.73, 95%CI 0.59–0.91).